HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Embarks On Rx-To-OTC Switch Revolution

Executive Summary

The Japanese government has approved a raft of measures aimed at expanding the country's consumer health market, including reforms to an Evaluation Committee that has not lived up to its promise of expediting Rx-to-OTC switches. 

You may also be interested in...

Takeda Exits Japan's OTC Market With Private-Equity Sale

Takeda is to offload its sizable Japanese OTC operation to private-equity firm Blackstone, which has committed to making the business the country's leading consumer health player.

Asia’s OTC Market Stunted By Regulatory Disharmony

HBW Insight Exclusive: A lack of regulatory harmonization, especially with regards to Rx-to-OTC switch, is holding the Asia-Pacific OTC market back, according to APSMI secretary general, Toshi Tominaga.

Takeda Divests Europe OTCs In $670m Deal As Rumors Swirl Of Japan Biz Sale

Takeda will divest a portfolio containing OTC drugs and dietary supplements to Denmark's Orifarm, while rumors suggest the company is poised to offload its substantial Japanese consumer healthcare business.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts